Preoperative chemotherapy response and survival in patients with colorectal cancer peritoneal metastases
Journal of Surgical Oncology · 2024
DOI: 10.1002/jso.27776 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2024. Verfasst von Nadina Tinsley und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. Hauptthemen laut MEDLINE: Peritoneal Neoplasms, Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Hyperthermic Intraperitoneal Chemotherapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Treatment guidelines provided by PRODIGE‐7 recommend perioperative systemic chemotherapy before cytoreductive surgery (CRS) for colorectal cancer peritoneal metastases (CRPM). Toxicity with multimodal treatment needs to be better defined. Chemotherapy response and impact on survival have not been reported. We assessed CRPM patients who received systemic oxaliplatin/irinotecan before CRS (preoperative) with Mitomycin C (35 mg/m 2 , 90 min) or Oxaliplatin (368 mg/m 2 , 30 min) heated intraperitoneal chemotherapy (HIPEC). Secondary analysis was performed from a prospective database. Overall survival (OS) in chemotherapy responders (R) and nonresponders (NR) was compared. Toxicity was assessed by rate of adverse events (AEs). From April 2005 to April 2021, 436 patients underwent CRS + HIPEC; 125 (29%) received preoperative chemotherapy. The 112 (90%) received oxaliplatin (64, 57%) or irinotecan (48, 43%). R, defined as complete (CR) or partial response on preoperative imaging and/or postoperative histology, was seen in 71, 63% (53.8–72.3); 16, 14% (8.4–22.2) had CR. Median OS in R versus NR was 43.7 months (37.9–49.4) versus 23.9 (16.3–31.4) p = 0.007, HR 0.51 (0.31–0.84). OS multivariable analysis showed HR 0.48 (0.25‐0.95), p = 0.03 for chemotherapy response corrected by peritoneal cancer index, completeness of cytoreduction score. CRS led to 21% grade 3–4 AEs versus 4% for preoperative chemotherapy. HIPEC grade 3‐4 AEs were 0.5%. Preoperative chemotherapy response is an independent predictor for OS in CRPM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
- Christie Peritoneal Oncology Centre (CPOC) at The Christie NHS Foundation Trust, Manchester, UK.
Zitieren
APA
Tinsley, N., O'Dwyer, S. T., Nagaraju, R., Chakrabarty, B., Braun, M., Mullamitha, S., Kamposioras, K., Marti Marti, F. E., Saunders, M., Clouston, H., Selvasekar, C., Wild, J., Wilson, M., Renehan, A., Aziz, O., & Barriuso, J. (2024). Preoperative chemotherapy response and survival in patients with colorectal cancer peritoneal metastases. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27776
Vancouver
Tinsley N, O'Dwyer ST, Nagaraju R, Chakrabarty B, Braun M, Mullamitha S, et al. Preoperative chemotherapy response and survival in patients with colorectal cancer peritoneal metastases. Journal of Surgical Oncology. 2024. doi:10.1002/jso.27776
BibTeX
@article{Tinsley2024,
author = {Tinsley, Nadina and O'Dwyer, Sarah T and Nagaraju, Raghavendar and Chakrabarty, Bipasha and Braun, Michael and Mullamitha, Saifee and Kamposioras, Konstantinos and Marti Marti, F E and Saunders, Mark and Clouston, Hamish and Selvasekar, Chelliah and Wild, Jonathan and Wilson, Malcolm and Renehan, Andrew and Aziz, Omer and Barriuso, Jorge},
title = {Preoperative chemotherapy response and survival in patients with colorectal cancer peritoneal metastases},
journal = {Journal of Surgical Oncology},
year = {2024},
doi = {10.1002/jso.27776}
}
EUVIMED